PT-141
PT-141 is a melanocortin receptor agonist approved as Vyleesi for HSDD, but off-label use concentrates on male erectile dysfunction and libido, with smaller traction for female dysfunction and general sexual enhancement. Clinician sources converge on 1.75 mg subcutaneous as needed, taken prior to sexual activity, with some sources noting a ceiling near 2 mg. Outcomes are highly variable across captured community reports: roughly half of male ED reports are positive, while positive reports for female dysfunction sit well below one in five.
Research Evidence
Evidence shape
PT-141 sits in the high-evidence tier, anchored by the strongest trials in hypoactive sexual desire disorder and female sexual arousal disorder. The work spans ten registered trials and eight indications with a combined enrollment of 2,089, yet only two indications have posted results, and the core evidence comes from four blinded trials backed by five distinct sponsors. The remaining five indications are thin, single-trial entries without posted results, plus one animal-only indication, so the majority of the catalog remains exploratory.
Anecdotal efficacy
Side effects
Clinical research side effects
Anecdotal side effects
Price
price offers can be sorted by column
Dosing & Protocol
How PT-141 is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
- Frequency
- as needed
- Timing
- unspecified
- Route
- subQ
- Cycle
- unspecified
9 completed trials identified; trial dosing not reliably extracted from registry data.
- Frequency
- daily
- Timing
- unspecified
- Route
- subQ
- Cycle
- unspecified
Clinician protocols dose 1 mg–2 mg daily subQ (4 sources).
- Frequency
- unspecified
- Timing
- unspecified
- Route
- subQ
- Cycle
- unspecified
Community reports cover female sexual dysfunction, male erectile dysfunction/libido, and general sexual enhancement. Efficacy is mixed across categories, with general sexual enhancement showing 100% positive reports based on a small sample. Dosing details from posts were not available to aggregate.
Peptide Deep Dive
Peptide Deep Dive is not projected for this peptide yet.
Regulatory safety notes
- • Transient increase in blood pressure and decrease in heart rate: Occurs after each dose and usually resolves within 12 hours. Consider the patient's cardiovascular risk before initiating VYLEESI and periodically during treatment and ensure blood pressure is w…
- • Focal hyperpigmentation: Reported by 1% of patients who received up to 8 doses per month, including involvement of the face, gingiva and breasts. Higher risk in patients with darker skin and with daily dosing. Resolution was not confirmed in some patients. Co…
- • Nausea: Reported by 40% of patients who received up to 8 monthly doses, requiring anti-emetic therapy in 13% of patients and leading to premature discontinuation for 8% of patients. Improved for most patients with the second dose. Consider discontinuing VYLEE…
- • VYLEESI is contraindicated in patients who have uncontrolled hypertension or known cardiovascular disease [see Warnings and Precautions (5.1) ]. Uncontrolled hypertension or known cardiovascular disease.
- • VYLEESI may slow gastric emptying and impact absorption of concomitantly administered oral medications. (7.1) VYLEESI may significantly decrease the systemic exposure of orally-administered naltrexone; avoid use with orally administered naltrexone-containing…
Peptide feedback
0 forum repliesLive community discussion for PT-141, shown here in the site layout and continued on the TVR forum.
No peptide feedback yet
Start the peptide feedback thread on the TVR forum.